Skip to main content
SpringerLink
Log in

Active Surveillance of Low-Risk Differentiated Thyroid Cancer

  • Chapter
  • First Online:
Controversies in Thyroid Nodules and Differentiated Thyroid Cancer

Abstract

While surgery remains the most utilized option for patients with low-risk papillary thyroid cancers (PTC), active surveillance is an alternative management strategy for selected patients with low-risk PTC in order to minimize risk of overtreatment and patient harm. This chapter describes selection criteria for patients who may be candidates for active surveillance, reviews the outcomes for active surveillance from previous long-term studies, and provides implementation strategies for how to carry out active surveillance protocols in a multidisciplinary setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–7.

    Article  CAS  PubMed  Google Scholar 

  2. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338–48.

    Article  PubMed  PubMed Central  Google Scholar 

  3. National Cancer Institute. Cancer Stat Facts: Thyroid Cancer. https://seer.cancer.gov/statfacts/html/thyro.html. Accessed June 1, 2021.

  4. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375(7):614–7.

    Article  PubMed  Google Scholar 

  5. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"—screening and overdiagnosis. N Engl J Med. 2014;371(19):1765–7.

    Article  PubMed  Google Scholar 

  6. Haymart MR, Banerjee M, Reyes-Gastelum D, Caoili E, Norton EC. Thyroid ultrasound and the increase in diagnosis of low-risk thyroid cancer. J Clin Endocrinol Metab. 2019;104(3):785–92.

    Article  PubMed  Google Scholar 

  7. Esfandiari NH, Hughes DT, Reyes-Gastelum D, Ward KC, Hamilton AS, Haymart MR. Factors associated with diagnosis and treatment of thyroid microcarcinomas. J Clin Endocrinol Metab. 2019;104(12):6060–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. SEER Cancer Statistics Review 1975–2017: Cancer of the Thyroid (Invasive). https://seer.cancer.gov/csr/1975_2017/browse_csr.php?sectionSEL=26&pageSEL=sect_26_table.22. Accessed June 1, 2021.

  9. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21(3):231–6.

    Article  PubMed  Google Scholar 

  10. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, Cronan JJ, Beland MD, Desser TS, Frates MC, Hammers LW, Hamper UM, Langer JE, Reading CC, Scoutt LM, Stavros AT. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14(5):587–95.

    Article  PubMed  Google Scholar 

  12. Lee SE, Kim EK, Moon HJ, Yoon JH, Park VY, Han K, Kwak JY. Guideline implementation on fine-needle aspiration for thyroid nodules: focusing on micronodules. Endocr Pract. 2020;26(9):1017–25.

    Article  PubMed  Google Scholar 

  13. Grani G, Lamartina L, Ascoli V, Bosco D, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, Durante C. Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: toward the "right" TIRADS. J Clin Endocrinol Metab. 2019;104(1):95–102.

    Article  PubMed  Google Scholar 

  14. Jeong C, Kim H, Lee J, Ha J, Kim MH, Kang MI, Lim DJ. Fine-needle aspiration of Subcentimeter thyroid nodules in the real-world management. Cancer Manag Res. 2020;12:7611–8.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Haymart MR, Esfandiari NH, Stang MT, Sosa JA. Controversies in the management of low-risk differentiated thyroid cancer. Endocr Rev. 2017;38(4):351–78.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Papaleontiou M, Chen DW, Banerjee M, Reyes-Gastelum D, Hamilton AS, Ward KC, Haymart MR. TSH suppression for papillary thyroid cancer: a physician survey study. Thyroid. 2021;31(9):1383–90.

    Google Scholar 

  17. Papaleontiou M, Hughes DT, Guo C, Banerjee M, Haymart MR. Population-based assessment of complications following surgery for thyroid cancer. J Clin Endocrinol Metab. 2017;102(7):2543–51.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228(3):320–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249–52.

    Article  CAS  PubMed  Google Scholar 

  20. Wang LY, Smith AW, Palmer FL, Tuttle RM, Mahrous A, Nixon IJ, Patel SG, Ganly I, Fagin JA, Boucai L. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid. 2015;25(3):300–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Papaleontiou M, Banerjee M, Reyes-Gastelum D, Hawley ST, Haymart MR. Risk of osteoporosis and fractures in patients with thyroid cancer: a case-control study in U.S. Veterans. Oncologist. 2019;24(9):1166–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Park J, Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Kirchhoff AC, Abraham D, Kim J, Monroe M, Hashibe M. Risk factors for cardiovascular disease among thyroid cancer survivors: findings from the Utah cancer survivors study. J Clin Endocrinol Metab. 2018;103(7):2468–77.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Pajamaki N, Metso S, Hakala T, Ebeling T, Huhtala H, Ryodi E, Sand J, Jukkola-Vuorinen A, Kellokumpu-Lehtinen PL, Jaatinen P. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clin Endocrinol. 2018;88(2):303–10.

    Article  Google Scholar 

  24. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, Miyauchi A. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13(4):381–7.

    Article  PubMed  Google Scholar 

  25. Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, Fujimoto Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34(6):1222–31.

    Article  PubMed  Google Scholar 

  26. Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, Untch B, Ganly I, Shaha AR, Shah JP, Pace M, Li D, Bach A, Lin O, Whiting A, Ghossein R, Landa I, Sabra M, Boucai L, Fish S, Morris LGT. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg. 2017;143(10):1015–20.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Oh HS, Ha J, Kim HI, Kim TH, Kim WG, Lim DJ, Kim TY, Kim SW, Kim WB, Shong YK, Chung JH, Baek JH. Active surveillance of low-risk papillary thyroid microcarcinoma: a multi-center cohort study in Korea. Thyroid. 2018;28(12):1587–94.

    Article  PubMed  Google Scholar 

  28. Moon JH, Kim JH, Lee EK, Lee KE, Kong SH, Kim YK, Jung WJ, Lee CY, Yoo RE, Hwangbo Y, Song YS, Kim MJ, Cho SW, Kim SJ, Jung EJ, Choi JY, Ryu CH, Lee YJ, Hah JH, Jung YS, Ryu J, Hwang Y, Park SK, Sung HK, Yi KH, Park DJ, Park YJ. Study protocol of multicenter prospective cohort study of active surveillance on papillary thyroid microcarcinoma (MAeSTro). Endocrinol Metab (Seoul). 2018;33(2):278–86.

    Article  PubMed  Google Scholar 

  29. Sanabria A. Active surveillance in thyroid microcarcinoma in a Latin-American cohort. JAMA Otolaryngol Head Neck Surg. 2018;144(10):947–8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, Bottici V, Viola D, Cappagli V, Valerio L, Giani C, Puleo L, Lorusso L, Piaggi P, Torregrossa L, Basolo F, Vitti P, Tuttle RM, Elisei R. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a Single Italian Center. J Clin Endocrinol Metab. 2020;105(3):e172–80.

    Article  PubMed  Google Scholar 

  31. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24(1):27–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Imai T, Kitano H, Sugitani I, Wada N. When can papillary microcarcinoma (papillary carcinoma measuring 1cm or less) be observed without immediate surgery? In: Takami H, editor. Treatment of thyroid tumor: Japanese clinical guidelines. Japan: Springer Japan; 2013. p. 119–22.

    Chapter  Google Scholar 

  33. Sugitani I, Ito Y, Takeuchi D, Nakayama H, Masaki C, Shindo H, Teshima M, Horiguchi K, Yoshida Y, Kanai T, Hirokawa M, Hames KY, Tabei I, Miyauchi A. Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma. Thyroid. 2021;31(2):183–92.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Haymart MR, Miller DC, Hawley ST. Active surveillance for low-risk cancers—a viable solution to overtreatment? N Engl J Med. 2017;377(3):203–6.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE, Protec TSG. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24.

    Article  PubMed  Google Scholar 

  36. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, Neal DE, Protec TSG. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Carter G, Clover K, Britton B, Mitchell AJ, White M, McLeod N, Denham J, Lambert SD. Wellbeing during active surveillance for localised prostate cancer: a systematic review of psychological morbidity and quality of life. Cancer Treat Rev. 2015;41(1):46–60.

    Article  PubMed  Google Scholar 

  38. Jeldres C, Cullen J, Hurwitz LM, Wolff EM, Levie KE, Odem-Davis K, Johnston RB, Pham KN, Rosner IL, Brand TC, L'Esperance JO, Sterbis JR, Etzioni R, Porter CR. Prospective quality-of-life outcomes for low-risk prostate cancer: active surveillance versus radical prostatectomy. Cancer. 2015;121(14):2465–73.

    Article  PubMed  Google Scholar 

  39. van den Bergh RC, Essink-Bot ML, Roobol MJ, Wolters T, Schroder FH, Bangma CH, Steyerberg EW. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009;115(17):3868–78.

    Article  PubMed  Google Scholar 

  40. Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D'Amico AV, Nguyen PL. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015. JAMA. 2019;321(7):704–6.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA. Active surveillance for low-risk prostate cancer in black patients. N Engl J Med. 2019;380(21):2070–2.

    Article  PubMed  PubMed Central  Google Scholar 

  42. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer, version 2.2021. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459. Accessed June 1, 2021.

  43. Esserman L, Yau C. Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol. 2015;1(7):881–3.

    Article  PubMed  Google Scholar 

  44. Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES. Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J Natl Cancer Inst. 2016;108(5):djv372.

    Article  PubMed  Google Scholar 

  45. Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, Collyar D, Bennett A, Kaplan C, Rosenberg S, Thompson A, Weiss A, Partridge A. The COMET (comparison of operative versus monitoring and endocrine therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797.

    Article  PubMed  PubMed Central  Google Scholar 

  46. National Cancer Institute. Cancer Stat Facts: Prostate Cancer. https://seer.cancer.gov/statfacts/html/prost.html. Accessed June 1, 2021.

  47. National Cancer Institute. Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html. Accessed June 1, 2021.

  48. Fukuoka O, Sugitani I, Ebina A, Toda K, Kawabata K, Yamada K. Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance. World J Surg. 2016;40(3):529–37.

    Article  PubMed  Google Scholar 

  49. Koshkina A, Fazelzad R, Sugitani I, Miyauchi A, Thabane L, Goldstein DP, Ghai S, Sawka AM. Association of patient age with progression of low-risk papillary thyroid carcinoma under active surveillance: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2020;146(6):552–60.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Papaleontiou M, Norton EC, Reyes-Gastelum D, Banerjee M, Haymart MR. Competing causes of death in older adults with thyroid cancer. Thyroid. 2021;31(9):1359–65.

    Google Scholar 

  51. Wang Z, Vyas CM, Van Benschoten O, Nehs MA, Moore FD Jr, Marqusee E, Krane JF, Kim MI, Heller HT, Gawande AA, Frates MC, Doubilet PM, Doherty GM, Cho NL, Cibas ES, Benson CB, Barletta JA, Zavacki AM, Larsen PR, Alexander EK, Angell TE. Quantitative analysis of the benefits and risk of thyroid nodule evaluation in patients >/=70 years old. Thyroid. 2018;28(4):465–71.

    Article  PubMed  Google Scholar 

  52. Lohia S, Gupta P, Curry M, Morris LGT, Roman BR. Life expectancy and treatment patterns in elderly patients with low-risk papillary thyroid cancer: a population-based analysis. Endocr Pract. 2021;27(3):228–35.

    Article  PubMed  Google Scholar 

  53. Sakai T, Sugitani I, Ebina A, Fukuoka O, Toda K, Mitani H, Yamada K. Active surveillance for T1bN0M0 papillary thyroid carcinoma. Thyroid. 2019;29(1):59–63.

    Article  PubMed  Google Scholar 

  54. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol. 2018;44(3):307–15.

    Article  CAS  PubMed  Google Scholar 

  55. Nam KH, Yoon JH, Chang HS, Park CS. Optimal timing of surgery in well-differentiated thyroid carcinoma detected during pregnancy. J Surg Oncol. 2005;91(3):199–203.

    Article  PubMed  Google Scholar 

  56. Yu SS, Bischoff LA. Thyroid cancer in pregnancy. Semin Reprod Med. 2016;34(6):351–5.

    Article  PubMed  Google Scholar 

  57. Ito Y, Miyauchi A, Kudo T, Ota H, Yoshioka K, Oda H, Sasai H, Nakayama A, Yabuta T, Masuoka H, Fukushima M, Higashiyama T, Kihara M, Kobayashi K, Miya A. Effects of pregnancy on papillary microcarcinomas of the thyroid re-evaluated in the entire patient series at Kuma Hospital. Thyroid. 2016;26(1):156–60.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J. 1999;46(1):209–16.

    Article  CAS  PubMed  Google Scholar 

  59. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ, Goellner JR. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144(6):980–7.

    Article  PubMed  Google Scholar 

  60. Pedrazzini L, Baroli A, Marzoli L, Guglielmi R, Papini E. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up. Minerva Endocrinol. 2013;38(3):269–79.

    CAS  PubMed  Google Scholar 

  61. Kim H, Park SY, Jung J, Kim JH, Hahn SY, Shin JH, Oh YL, Chung MK, Kim HI, Kim SW, Chung JH, Kim TH. Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer. Sci Rep. 2019;9(1):18745.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Ito Y, Miyauchi A, Oda H, Kobayashi K, Kihara M, Miya A. Revisiting low-risk thyroid papillary microcarcinomas resected without observation: was immediate surgery necessary? World J Surg. 2016;40(3):523–8.

    Article  PubMed  Google Scholar 

  63. Kovatch KJ, Reyes-Gastelum D, Sipos JA, Caoili EM, Hamilton AS, Ward KC, Haymart MR. Physician confidence in neck ultrasonography for surveillance of differentiated thyroid cancer recurrence. JAMA Otolaryngol Head Neck Surg. 2020;147(2):166–72.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Elwyn G, Hutchings H, Edwards A, Rapport F, Wensing M, Cheung WY, Grol R. The OPTION scale: measuring the extent that clinicians involve patients in decision-making tasks. Health Expect. 2005;8(1):34–42.

    Article  PubMed  PubMed Central  Google Scholar 

  65. D'Agostino TA, Shuk E, Maloney EK, Zeuren R, Tuttle RM, Bylund CL. Treatment decision making in early-stage papillary thyroid cancer. Psychooncology. 2018;27(1):61–8.

    Article  PubMed  Google Scholar 

  66. Thompson EG, Husney A, Romito K, Wood CG, Hoffman RM. Prostate cancer: should I choose active surveillance? https://www.upmc.com/health-library/article?hwid=abo8743&locale=en-us. Accessed June 1, 2021.

  67. Smulever A, Pitoia F. High rate incidence of post-surgical adverse events in patients with low-risk papillary thyroid cancer who did not accept active surveillance. Endocrine. 2020;69(3):587–95.

    Article  CAS  PubMed  Google Scholar 

  68. Oda H, Miyauchi A, Ito Y, Yoshioka K, Nakayama A, Sasai H, Masuoka H, Yabuta T, Fukushima M, Higashiyama T, Kihara M, Kobayashi K, Miya A. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. Thyroid. 2016;26(1):150–5.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Kong SH, Ryu J, Kim MJ, Cho SW, Song YS, Yi KH, Park DJ, Hwangbo Y, Lee YJ, Lee KE, Kim SJ, Jeong WJ, Chung EJ, Hah JH, Choi JY, Ryu CH, Jung YS, Moon JH, Lee EK, Park YJ. Longitudinal assessment of quality of life according to treatment options in low-risk papillary thyroid microcarcinoma patients: active surveillance or immediate surgery (interim analysis of MAeSTro). Thyroid. 2019;29(8):1089–96.

    Article  CAS  PubMed  Google Scholar 

  70. Jeon M, Lee YM, Sung TY, Han M, Shin YW, Kim WG, Kim TY, Chung KW, Shong Y, Kim WB. Quality of life in patients with papillary thyroid microcarcinoma managed by active surveillance or lobectomy : a cross-sectional study. Thyroid. 2019;29(7):956–62.

    Article  CAS  PubMed  Google Scholar 

  71. Nakamura T, Miyauchi A, Ito Y, Ito M, Kudo T, Tanaka M, Kohsaka K, Kasahara T, Nishihara E, Fukata S, Nishikawa M. Quality of life in patients with low-risk papillary thyroid microcarcinoma: active surveillance versus immediate surgery. Endocr Pract. 2020;26(12):1451–7.

    Article  PubMed  Google Scholar 

  72. White C, Weinstein MC, Fingeret AL, Randolph GW, Miyauchi A, Ito Y, Zhan T, Ali A, Gazelle GS, Lubitz CC. Is less more? A microsimulation model comparing cost-effectiveness of the revised American Thyroid Association's 2015 to 2009 guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer. Ann Surg. 2020;271(4):765–73.

    Article  PubMed  Google Scholar 

  73. Lin JF, Jonker PKC, Cunich M, Sidhu SB, Delbridge LW, Glover AR, Learoyd DL, Aniss A, Kruijff S, Sywak MS. Surgery alone for papillary thyroid microcarcinoma is less costly and more effective than long term active surveillance. Surgery. 2020;167(1):110–6.

    Article  PubMed  Google Scholar 

  74. Pitt SC, Yang N, Saucke MC, Marka N, Hanlon B, Long KL, McDow AD, Brito JP, Roman BR. Adoption of active surveillance for very low-risk differentiated thyroid cancer in the United States: a National Survey. J Clin Endocrinol Metab. 2021;106(4):e1728–37.

    Article  PubMed  Google Scholar 

  75. Hughes DT, Reyes-Gastelum D, Ward KC, Hamilton AS, Haymart MR. Barriers to the use of active surveillance for thyroid cancer: results of a physician survey. Ann Surg. 2022;276(1):e40–7.

    Google Scholar 

  76. Pitt SC, Saucke MC, Wendt EM, Schneider DF, Orne J, Macdonald CL, Connor NP, Sippel RS. Patients' reaction to diagnosis with thyroid cancer or an indeterminate thyroid nodule. Thyroid. 2021;31(4):580–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Dixon PR, Tomlinson G, Pasternak JD, Mete O, Bell CM, Sawka AM, Goldstein DP, Urbach DR. The role of disease label in patient perceptions and treatment decisions in the setting of low-risk malignant neoplasms. JAMA Oncol. 2019;5(6):817–23.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Nickel B, Barratt A, McGeechan K, Brito JP, Moynihan R, Howard K, McCaffery K. Effect of a change in papillary thyroid cancer terminology on anxiety levels and treatment preferences: a randomized crossover trial. JAMA Otolaryngol Head Neck Surg. 2018;144(10):867–74.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Sawka AM, Ghai S, Yoannidis T, Rotstein L, Gullane PJ, Gilbert RW, Pasternak JD, Brown DH, Eskander A, Almeida JR, Irish JC, Higgins K, Enepekides DJ, Monteiro E, Banerjee A, Shah M, Gooden E, Zahedi A, Korman M, Ezzat S, Jones JM, Rac VE, Tomlinson G, Stanimirovic A, Gafni A, Baxter NN, Goldstein DP. A prospective mixed-methods study of decision-making on surgery or active surveillance for low-risk papillary thyroid cancer. Thyroid. 2020;30(7):999–1007.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Sugitani I, Ito Y, Miyauchi A, Imai T, Suzuki S. Active surveillance versus immediate surgery: questionnaire survey on the current treatment strategy for adult patients with low-risk papillary thyroid microcarcinoma in Japan. Thyroid. 2019;29(11):1563–71.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA

    Debbie W. Chen & Megan R. Haymart

Authors
  1. Debbie W. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megan R. Haymart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Megan R. Haymart .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of California, San Francisco, San Francisco, CA, USA

    Sanziana A. Roman

  2. Department of Surgery, University of California, San Francisco, San Francisco, CA, USA

    Wen T. Shen

  3. Department of Surgery, University of California, San Francisco, San Francisco, CA, USA

    Julie Ann Sosa

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chen, D.W., Haymart, M.R. (2023). Active Surveillance of Low-Risk Differentiated Thyroid Cancer. In: Roman, S.A., Shen, W.T., Sosa, J.A. (eds) Controversies in Thyroid Nodules and Differentiated Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-031-37135-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-37135-6_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-37134-9

  • Online ISBN: 978-3-031-37135-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation